Daniel Getts
Dr Getts is the founding Chief Scientific Officer of Myeloid Therapeutics Inc. Prior to Myeloid Therapeutics Inc he was VP of Research at TCR2 (NASDAQ, TCRR), he was member of the leadership team that guided the company successfully through a series B ($120M) financing and an IPO (~$80M). Dr Getts lead the companies target discovery, preclinical and translational research programs. These efforts resulted in a numerous patent applications, a robust pipeline and a successfully filed IND. Prior to TCR2 Dr Getts was primary inventor, founder and Chief Scientific Officer of Cour Pharmaceutical Development Company, a nanotechnology company focused on immune disorders. In this role Dr Getts oversaw pipeline development and IND development of TIMP-GLIA a novel nanoparticle treatment for Celiac disease. Dr Getts assisted in the negotiation of a number of pharmaceutical company collaborations, including with Takeda, whom licensed the lead compound for $420M plus royalties. He also served as Director, Research & Development at Tolera Therapeutics where he was responsible for advancing the company's monoclonal ABTCR antibody program. A recipient of numerous honors and awards, including >10 issued patents and more than 25 pending patent applications. Daniel is widely published with >40 peer-reviewed publications, with seminal publications in Nature Biotechnology and Science Translational Medicine. He completed his Postdoctoral training in Stephen D. Miller's laboratory at Northwestern University. He holds a PhD in Medicine from the University of Sydney and a MBA from Western Michigan University.
Abstracts this author is presenting: